Trial Profile
PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Goserelin; Letrozole; Tamoxifen
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms PREDIX LumA
- 10 Dec 2022 Status changed to discontinued, according to Results presented at the 45th Annual San Antonio Breast Cancer Symposium
- 05 Jul 2020 Planned End Date changed from 1 Dec 2024 to 1 Feb 2029.
- 05 Jul 2020 Status changed from recruiting to active, no longer recruiting.